Cargando…

The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial

The aim of this clinical trial was to control the cytokine storm by administering mesenchymal stem cells (MSCs) to critically-ill COVID-19 patients, to evaluate the healing effect, and to systematically investigate how the treatment works. Patients with moderate and critical COVID-19 clinical manife...

Descripción completa

Detalles Bibliográficos
Autores principales: Adas, G, Cukurova, Z, Yasar, K Kart, Yilmaz, R, Isiksacan, N, Kasapoglu, P, Yesilbag, Z, Koyuncu, ID, Karaoz, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243094/
https://www.ncbi.nlm.nih.gov/pubmed/34180719
http://dx.doi.org/10.1177/09636897211024942
_version_ 1783715700748058624
author Adas, G
Cukurova, Z
Yasar, K Kart
Yilmaz, R
Isiksacan, N
Kasapoglu, P
Yesilbag, Z
Koyuncu, ID
Karaoz, E
author_facet Adas, G
Cukurova, Z
Yasar, K Kart
Yilmaz, R
Isiksacan, N
Kasapoglu, P
Yesilbag, Z
Koyuncu, ID
Karaoz, E
author_sort Adas, G
collection PubMed
description The aim of this clinical trial was to control the cytokine storm by administering mesenchymal stem cells (MSCs) to critically-ill COVID-19 patients, to evaluate the healing effect, and to systematically investigate how the treatment works. Patients with moderate and critical COVID-19 clinical manifestations were separated as Group 1 (moderate cases, n = 10, treated conventionally), Group 2 (critical cases, n = 10, treated conventionally), and Group 3 (critical cases, n = 10, treated conventionally plus MSCs transplantation therapy of three consecutive doses on treatment days 0, 3, and 6, (as 3 × 10(6) cells/kg, intravenously). The treatment mechanism of action was investigated with evaluation markers of the cytokine storm, via biochemical parameters, levels of proinflammatory and anti-inflammatory cytokines, analyses of tissue regeneration via the levels of growth factors, apoptosis markers, chemokines, matrix metalloproteinases, and granzyme-B, and by the assessment of the immunomodulatory effects via total oxidant/antioxidant status markers and the levels of lymphocyte subsets. In the assessment of the overall mortality rates of all the cases, six patients in Group-2 and three patients in Group-3 died, and there was no loss in Group-1. Proinflammatory cytokines IFNγ, IL-6, IL-17A, IL-2, IL-12, anti-inflammatory cytokines IL-10, IL-13, IL-1ra, and growth factors TGF-β, VEGF, KGF, and NGF levels were found to be significant in Group-3. When Group-2 and Group-3 were compared, serum ferritin, fibrinogen and CRP levels in Group-3 had significantly decreased. CD45 +, CD3 +, CD4 +, CD8 +, CD19 +, HLA-DR +, and CD16 + / CD56 + levels were evaluated. In the statistical comparison of the groups, significance was only determined in respect of neutrophils. The results demonstrated the positive systematic and cellular effects of MSCs application on critically ill COVID-19 patients in a versatile way. This effect plays an important role in curing and reducing mortality in critically ill patients.
format Online
Article
Text
id pubmed-8243094
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-82430942021-07-13 The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial Adas, G Cukurova, Z Yasar, K Kart Yilmaz, R Isiksacan, N Kasapoglu, P Yesilbag, Z Koyuncu, ID Karaoz, E Cell Transplant Original Article The aim of this clinical trial was to control the cytokine storm by administering mesenchymal stem cells (MSCs) to critically-ill COVID-19 patients, to evaluate the healing effect, and to systematically investigate how the treatment works. Patients with moderate and critical COVID-19 clinical manifestations were separated as Group 1 (moderate cases, n = 10, treated conventionally), Group 2 (critical cases, n = 10, treated conventionally), and Group 3 (critical cases, n = 10, treated conventionally plus MSCs transplantation therapy of three consecutive doses on treatment days 0, 3, and 6, (as 3 × 10(6) cells/kg, intravenously). The treatment mechanism of action was investigated with evaluation markers of the cytokine storm, via biochemical parameters, levels of proinflammatory and anti-inflammatory cytokines, analyses of tissue regeneration via the levels of growth factors, apoptosis markers, chemokines, matrix metalloproteinases, and granzyme-B, and by the assessment of the immunomodulatory effects via total oxidant/antioxidant status markers and the levels of lymphocyte subsets. In the assessment of the overall mortality rates of all the cases, six patients in Group-2 and three patients in Group-3 died, and there was no loss in Group-1. Proinflammatory cytokines IFNγ, IL-6, IL-17A, IL-2, IL-12, anti-inflammatory cytokines IL-10, IL-13, IL-1ra, and growth factors TGF-β, VEGF, KGF, and NGF levels were found to be significant in Group-3. When Group-2 and Group-3 were compared, serum ferritin, fibrinogen and CRP levels in Group-3 had significantly decreased. CD45 +, CD3 +, CD4 +, CD8 +, CD19 +, HLA-DR +, and CD16 + / CD56 + levels were evaluated. In the statistical comparison of the groups, significance was only determined in respect of neutrophils. The results demonstrated the positive systematic and cellular effects of MSCs application on critically ill COVID-19 patients in a versatile way. This effect plays an important role in curing and reducing mortality in critically ill patients. SAGE Publications 2021-06-28 /pmc/articles/PMC8243094/ /pubmed/34180719 http://dx.doi.org/10.1177/09636897211024942 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Adas, G
Cukurova, Z
Yasar, K Kart
Yilmaz, R
Isiksacan, N
Kasapoglu, P
Yesilbag, Z
Koyuncu, ID
Karaoz, E
The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial
title The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial
title_full The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial
title_fullStr The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial
title_full_unstemmed The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial
title_short The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial
title_sort systematic effect of mesenchymal stem cell therapy in critical covid-19 patients: a prospective double controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243094/
https://www.ncbi.nlm.nih.gov/pubmed/34180719
http://dx.doi.org/10.1177/09636897211024942
work_keys_str_mv AT adasg thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT cukurovaz thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT yasarkkart thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT yilmazr thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT isiksacann thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT kasapoglup thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT yesilbagz thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT koyuncuid thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT karaoze thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT adasg systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT cukurovaz systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT yasarkkart systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT yilmazr systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT isiksacann systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT kasapoglup systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT yesilbagz systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT koyuncuid systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial
AT karaoze systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial